These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists. Dzierba CD; Sielecki TM; Arvanitis AG; Galka A; Johnson TL; Takvorian AG; Rafalski M; Kasireddy-Polam P; Vig S; Dasgupta B; Zhang G; Molski TF; Wong H; Zaczek RC; Lodge NJ; Combs AP; Gilligan PJ; Trainor GL; Bronson JJ; Macor JE Bioorg Med Chem Lett; 2012 Aug; 22(15):4986-9. PubMed ID: 22749422 [TBL] [Abstract][Full Text] [Related]
8. CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine. Arvanitis AG; Arnold CR; Fitzgerald LW; Frietze WE; Olson RE; Gilligan PJ; Robertson DW Bioorg Med Chem Lett; 2003 Jan; 13(2):289-91. PubMed ID: 12482442 [TBL] [Abstract][Full Text] [Related]
9. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists. Zuev D; Vrudhula VM; Michne JA; Dasgupta B; Pin SS; Huang XS; Wu D; Gao Q; Zhang J; Taber MT; Macor JE; Dubowchik GM Bioorg Med Chem Lett; 2010 Jun; 20(12):3669-74. PubMed ID: 20471832 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists. Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-a]pyrazines. Bonnet PA; Michel A; Laurent F; Sablayrolles C; Rechencq E; Mani JC; Boucard M; Chapat JP J Med Chem; 1992 Sep; 35(18):3353-8. PubMed ID: 1527785 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors. Stehouwer JS; Bourke CH; Owens MJ; Voll RJ; Kilts CD; Goodman MM Bioorg Med Chem Lett; 2015 Nov; 25(22):5111-4. PubMed ID: 26456805 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists. Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists. Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881 [TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase. Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines. Marchand P; Bazin MA; Pagniez F; Rivière G; Bodero L; Marhadour S; Nourrisson MR; Picot C; Ruchaud S; Bach S; Baratte B; Sauvain M; Pareja DC; Vaisberg AJ; Le Pape P Eur J Med Chem; 2015 Oct; 103():381-95. PubMed ID: 26383125 [TBL] [Abstract][Full Text] [Related]
20. Antiulcer agents. 3. Structure-activity-toxicity relationships of substituted imidazo[1,2-a]pyridines and a related imidazo[1,2-a]pyrazine. Kaminski JJ; Perkins DG; Frantz JD; Solomon DM; Elliott AJ; Chiu PJ; Long JF J Med Chem; 1987 Nov; 30(11):2047-51. PubMed ID: 3669012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]